Clinical Trials Browser

Active not recruiting × INDUSTRY × relmacabtagene autoleucel × Clear all

NCT06093841 2025-02-11

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse